SYM FINANCIAL Corp lowered its stake in shares of Eli Lilly And Co (NYSE:LLY) by 43.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,588 shares of the company’s stock after selling 4,249 shares during the period. Eli Lilly And Co makes up 0.4% of SYM FINANCIAL Corp’s portfolio, making the stock its 13th biggest position. SYM FINANCIAL Corp’s holdings in Eli Lilly And Co were worth $625,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Eli Lilly And Co by 0.8% during the 2nd quarter. Vanguard Group Inc. now owns 71,134,378 shares of the company’s stock valued at $7,880,977,000 after purchasing an additional 578,045 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Eli Lilly And Co by 1.5% during the 2nd quarter. BlackRock Inc. now owns 61,979,145 shares of the company’s stock valued at $6,866,670,000 after purchasing an additional 898,845 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Eli Lilly And Co by 0.3% during the 2nd quarter. Northern Trust Corp now owns 11,056,098 shares of the company’s stock valued at $1,224,906,000 after purchasing an additional 32,421 shares in the last quarter. Nuveen Asset Management LLC lifted its holdings in shares of Eli Lilly And Co by 20,030.9% during the 2nd quarter. Nuveen Asset Management LLC now owns 7,265,844 shares of the company’s stock valued at $804,983,000 after purchasing an additional 7,229,751 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. lifted its holdings in shares of Eli Lilly And Co by 13.2% during the 2nd quarter. Amundi Pioneer Asset Management Inc. now owns 5,422,106 shares of the company’s stock valued at $600,715,000 after purchasing an additional 632,573 shares in the last quarter. Hedge funds and other institutional investors own 77.22% of the company’s stock.

LLY has been the topic of several recent analyst reports. UBS Group cut their price objective on Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating on the stock in a report on Thursday, October 17th. Bank of America initiated coverage on Eli Lilly And Co in a report on Wednesday, October 16th. They set a “buy” rating and a $133.00 price objective on the stock. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $130.03.

In related news, Director Jackson P. Tai purchased 1,861 shares of the stock in a transaction on Thursday, October 24th. The shares were purchased at an average price of $107.49 per share, with a total value of $200,038.89. Following the transaction, the director now directly owns 56,440 shares of the company’s stock, valued at $6,066,735.60. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 173,918 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $114.05, for a total value of $19,835,347.90. Following the transaction, the insider now directly owns 116,229,383 shares in the company, valued at approximately $13,255,961,131.15. The disclosure for this sale can be found here. In the last 90 days, insiders acquired 8,405 shares of company stock worth $909,004 and sold 614,373 shares worth $70,546,895. Insiders own 0.11% of the company’s stock.

NYSE LLY traded up $0.76 during trading on Friday, hitting $113.53. The stock had a trading volume of 2,217,880 shares, compared to its average volume of 7,683,282. The company has a market capitalization of $106.81 billion, a PE ratio of 20.46, a P/E/G ratio of 1.82 and a beta of 0.16. The company’s 50-day moving average price is $110.64 and its two-hundred day moving average price is $112.68. The company has a debt-to-equity ratio of 4.09, a quick ratio of 0.88 and a current ratio of 1.17. Eli Lilly And Co has a 12 month low of $101.36 and a 12 month high of $132.13.

Eli Lilly And Co (NYSE:LLY) last released its earnings results on Wednesday, October 23rd. The company reported $1.48 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.43 by $0.05. The firm had revenue of $5.48 billion for the quarter, compared to analysts’ expectations of $5.50 billion. Eli Lilly And Co had a return on equity of 107.99% and a net margin of 35.10%. The business’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.39 EPS. As a group, equities analysts anticipate that Eli Lilly And Co will post 5.78 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be paid a $0.645 dividend. This represents a $2.58 annualized dividend and a yield of 2.27%. The ex-dividend date of this dividend is Thursday, November 14th. Eli Lilly And Co’s payout ratio is 46.49%.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: Basic Economics

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.